Atypical responses to neoadjuvant chemotherapy combined with accelerated partial breast tumor-directed radiotherapy: two cases and considerations for future clinical trials

Nhu Hanh To; Myriam Kossai; Nabila Ouidir; Noemie Grellier; Elias Assaf; Isabelle Gabelle-Flandin; Yazid Belkacemi; Nina Radosevic-Robin

doi:10.5603/RPOR.a2022.0112

Atypical responses to neoadjuvant chemotherapy combined with accelerated partial breast tumor-directed radiotherapy: two cases and considerations for future clinical trials

Rep Pract Oncol Radiother. 2022 Dec 29;27(6):1114-1118. doi: 10.5603/RPOR.a2022.0112. eCollection 2022.

Authors

Nhu Hanh To^{1

2

3

4}, Myriam Kossai^{5

6}, Nabila Ouidir⁷, Noemie Grellier¹, Elias Assaf⁸, Isabelle Gabelle-Flandin⁹, Yazid Belkacemi^#^{1

2

3

4

10}, Nina Radosevic-Robin^#^{5

6

10}

Affiliations

¹ Department of Radiation Oncology and The Henri Mondor Breast Center, The Henri Mondor University Hospital, Creteil, France.
² University of Paris-Est Créteil (UPEC), Creteil, France.
³ INSERM Unit 955, Immunoregulation and Biotherapy (I-Biot) Team, The Mondor Institute for Biomedical Research (IMRB), Creteil, France.
⁴ Transatlantic Radiation Oncology Network (TRONE), Créteil, France.
⁵ Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France.
⁶ University Clermont Auvergne, INSERM Unit 1240 (IMoST), Radiopharmaceuticals & Biomarkers (RoBust) Team, Clermont-Ferrand, France.
⁷ Department of Pathology, The Henri Mondor University Hospital, AP-HP, Creteil, France.
⁸ Department of Medical Oncology, The Henri Mondor University Hospital, Creteil, France.
⁹ University Clinic of Cancerology-Radiotherapy, The Grenoble Alpes University Hospital Centre, La Tronche, France.
¹⁰ Association of Radiation Oncologists in the Mediterranean region (AROME), Creteil, France.

^# Contributed equally.

No abstract available

Keywords: exceptional response; neoadjuvant; p53/pRb; radiotherapy; triple-negative breast cancer.